The Dawn of Eurosimilarity

  • by: |
  • 06/21/2012
Perhaps we should call them "Eurosimilars."

According to the Pink Sheet, European Health Commissioner John Dalli has announced that the EU would be prepared to accept applications for biosimilar products with data from original biologic medicines that are not sourced from within the Union. The move, while expected, will breathe new life into a stagnant industry sector with few EU authorizations each year and is likely to send pharmaceutical manufacturers the surest signal yet that this is time to jump quickly onto the bandwagon.

Speaking at the European Generic medicines Association (EGA) annual meeting, Dalli acknowledged that while Europe had lit the touch paper of biosimilars development by coming up with the first regulatory framework, the explosion of biosimilars across the globe was gathering pace at an impressive rate. “I believe that this is a natural and positive trend, but I realize that the application of the EU rules on biosimilars do not fully match this trend,” he said. He added that the EU was ready to rectify this situation.

While Dalli’s announcement represents a significant boost for biosimilars manufacturers, the real icing on the cake is that EU acceptance of third-country comparability data could happen very quickly. This is because the commission now says that such a move only requires a re-interpreting the law, rather than a full-fledged legislative process, which could take up to five years. This would be accompanied by an update of the overarching guideline.The global development concept is also gathering pace in the U.S., where draft guidance suggests that “under certain circumstances” a sponsor might use data from studies comparing a proposed product with a non-U.S.-licensed product. FDA has confirmed in writing that an EU-referenced product could be used in comparative trials for application in the U.S. (Please note the use of the conditional “could.”)

The complete Pink Sheet story can be found here.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog